NZ755599A - Apoc-ii mimetic peptides - Google Patents
Apoc-ii mimetic peptidesInfo
- Publication number
- NZ755599A NZ755599A NZ755599A NZ75559918A NZ755599A NZ 755599 A NZ755599 A NZ 755599A NZ 755599 A NZ755599 A NZ 755599A NZ 75559918 A NZ75559918 A NZ 75559918A NZ 755599 A NZ755599 A NZ 755599A
- Authority
- NZ
- New Zealand
- Prior art keywords
- peptide
- apoc
- mimetic
- seq
- mimetic peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 19
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract 5
- 201000011110 familial lipoprotein lipase deficiency Diseases 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000001021 Hyperlipoproteinemia Type I Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 101150062900 lpl gene Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 108010024284 Apolipoprotein C-II Proteins 0.000 abstract 3
- 102100039998 Apolipoprotein C-II Human genes 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448358P | 2017-01-19 | 2017-01-19 | |
| US201762476531P | 2017-03-24 | 2017-03-24 | |
| US201762476535P | 2017-03-24 | 2017-03-24 | |
| PCT/US2018/014532 WO2018136803A1 (fr) | 2017-01-19 | 2018-01-19 | Peptides mimétiques d'apoc-ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ755599A true NZ755599A (en) | 2022-12-23 |
Family
ID=62908746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ755599A NZ755599A (en) | 2017-01-19 | 2018-01-19 | Apoc-ii mimetic peptides |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11136372B2 (fr) |
| EP (1) | EP3571216A4 (fr) |
| JP (2) | JP7353973B2 (fr) |
| KR (1) | KR20190121305A (fr) |
| CN (1) | CN110831957B (fr) |
| AU (1) | AU2018210404B2 (fr) |
| BR (1) | BR112019014707A2 (fr) |
| CA (1) | CA3050106A1 (fr) |
| IL (2) | IL268093B2 (fr) |
| MX (1) | MX2019008529A (fr) |
| NZ (1) | NZ755599A (fr) |
| SG (2) | SG10201911974UA (fr) |
| TW (2) | TWI788323B (fr) |
| WO (1) | WO2018136803A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201911974UA (en) | 2017-01-19 | 2020-02-27 | The United States Of America As Represented By The Secretary Department Of Health & Human Services | Apoc-ii mimetic peptides |
| EP4359432A2 (fr) * | 2021-06-23 | 2024-05-01 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Peptides mimétiques d'apoc-ii courts et méthodes d'utilisation |
| WO2023215838A1 (fr) * | 2022-05-05 | 2023-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptides mimétiques d'apolipoprotéine e courte et procédés d'utilisation |
| WO2024036145A1 (fr) * | 2022-08-07 | 2024-02-15 | Protean Bio, Inc. | Peptides pour la survie de cellules bêta et la production d'insuline |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1998009602A2 (fr) * | 1996-09-05 | 1998-03-12 | The Uab Research Foundation | Peptides anti-atherosclereux et modele murin transgenique d'atherosclerose |
| AU2002362612B2 (en) | 2001-09-28 | 2007-11-15 | Cedars-Sinai Medical Center | Prevention and treatment of restenosis by local administration of drug |
| US7220576B2 (en) * | 2002-01-07 | 2007-05-22 | Lifesensors, Inc. | Methods and compositions for protein expression and purification |
| US7691965B2 (en) * | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| WO2004066963A2 (fr) * | 2003-01-17 | 2004-08-12 | Merck & Co., Inc. | Derives de n-cyclohexylaminocarbonyl benzenesulfonamide |
| US7691860B2 (en) * | 2004-02-19 | 2010-04-06 | Banyu Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
| CN101076541A (zh) * | 2004-07-16 | 2007-11-21 | 塔夫茨大学信托人 | 载脂蛋白a1模拟物及其用途 |
| AU2006263332B2 (en) * | 2005-06-29 | 2012-02-23 | Hadasit Medical Research Services & Development Ltd. | Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes |
| US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| WO2009097584A1 (fr) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Biomarqueurs de sérum maternel pour la détection de pré-éclampsie |
| US8936787B2 (en) * | 2008-04-15 | 2015-01-20 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Peptides promoting lipid efflux |
| WO2011040654A1 (fr) | 2009-09-30 | 2011-04-07 | 서울대학교산학협력단 | Peptides mimétiques d'apolipoprotéine a-1, et agent thérapeutique pour traiter l'hyperlipidémie et maladies associées à l'hyperlipidémie comprenant ceux-ci |
| JP6499967B2 (ja) * | 2012-11-06 | 2019-04-10 | レ オピト ユニベルシテル ドゥ ジュネーブＬｅｓ Ｈｏｐｉｔａｕｘ Ｕｎｉｖｅｒｓｉｔａｉｒｅｓ Ｄｅ Ｇｅｎｅｖｅ | 模倣ペプチド |
| SG10201911974UA (en) | 2017-01-19 | 2020-02-27 | The United States Of America As Represented By The Secretary Department Of Health & Human Services | Apoc-ii mimetic peptides |
| EA201991491A1 (ru) | 2017-03-24 | 2019-12-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис | Миметические пептиды apoc-ii |
-
2018
- 2018-01-19 SG SG10201911974UA patent/SG10201911974UA/en unknown
- 2018-01-19 TW TW107102123A patent/TWI788323B/zh active
- 2018-01-19 WO PCT/US2018/014532 patent/WO2018136803A1/fr active Application Filing
- 2018-01-19 KR KR1020197024024A patent/KR20190121305A/ko not_active Application Discontinuation
- 2018-01-19 US US16/479,183 patent/US11136372B2/en active Active
- 2018-01-19 TW TW109138699A patent/TW202130652A/zh unknown
- 2018-01-19 SG SG11201906422VA patent/SG11201906422VA/en unknown
- 2018-01-19 BR BR112019014707A patent/BR112019014707A2/pt unknown
- 2018-01-19 EP EP18742118.5A patent/EP3571216A4/fr active Pending
- 2018-01-19 MX MX2019008529A patent/MX2019008529A/es unknown
- 2018-01-19 IL IL268093A patent/IL268093B2/en unknown
- 2018-01-19 JP JP2019539809A patent/JP7353973B2/ja active Active
- 2018-01-19 CN CN201880019604.7A patent/CN110831957B/zh active Active
- 2018-01-19 AU AU2018210404A patent/AU2018210404B2/en active Active
- 2018-01-19 CA CA3050106A patent/CA3050106A1/fr active Pending
- 2018-01-19 NZ NZ755599A patent/NZ755599A/en unknown
-
2020
- 2020-12-29 IL IL279831A patent/IL279831A/en unknown
-
2021
- 2021-03-09 US US17/195,766 patent/US11827690B2/en active Active
-
2023
- 2023-06-19 JP JP2023100171A patent/JP2023116739A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110831957A (zh) | 2020-02-21 |
| CN110831957B (zh) | 2024-02-09 |
| KR20190121305A (ko) | 2019-10-25 |
| WO2018136803A8 (fr) | 2019-08-01 |
| WO2018136803A1 (fr) | 2018-07-26 |
| SG10201911974UA (en) | 2020-02-27 |
| IL268093A (en) | 2019-09-26 |
| IL268093B2 (en) | 2024-07-01 |
| JP2023116739A (ja) | 2023-08-22 |
| IL279831A (en) | 2021-03-01 |
| AU2018210404B2 (en) | 2022-01-27 |
| AU2018210404A1 (en) | 2019-08-08 |
| JP7353973B2 (ja) | 2023-10-02 |
| JP2020511425A (ja) | 2020-04-16 |
| MX2019008529A (es) | 2020-02-07 |
| US11827690B2 (en) | 2023-11-28 |
| US11136372B2 (en) | 2021-10-05 |
| US20200140522A1 (en) | 2020-05-07 |
| SG11201906422VA (en) | 2019-08-27 |
| IL268093B1 (en) | 2024-03-01 |
| TWI788323B (zh) | 2023-01-01 |
| EP3571216A4 (fr) | 2020-11-04 |
| TW201835097A (zh) | 2018-10-01 |
| BR112019014707A2 (pt) | 2020-04-07 |
| CA3050106A1 (fr) | 2018-07-26 |
| US20210324043A1 (en) | 2021-10-21 |
| EP3571216A1 (fr) | 2019-11-27 |
| TW202130652A (zh) | 2021-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ755599A (en) | Apoc-ii mimetic peptides | |
| Marr et al. | Antibacterial peptides for therapeutic use: obstacles and realistic outlook | |
| EP1853620B1 (fr) | Hexapeptides antimicrobiens | |
| Conlon et al. | Strategies for transformation of naturally-occurring amphibian antimicrobial peptides into therapeutically valuable anti-infective agents | |
| Laverty et al. | The potential of antimicrobial peptides as biocides | |
| Steinstraesser et al. | Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| Kyriakopoulos et al. | Analysis of the landscape of biologically-derived pharmaceuticals in Europe: dominant production systems, molecule types on the rise and approval trends | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| EA039105B1 (ru) | Катионные нейротоксины | |
| KR20180002710A (ko) | 항균 요법 | |
| NZ596778A (en) | Glucose-regulating polypeptides and methods of making and using same | |
| Kamei et al. | Noninvasive insulin delivery: the great potential of cell-penetrating peptides | |
| US20210196794A1 (en) | Fgf21 variant, fusion protein and application thereof | |
| CN102083855A (zh) | 活性延长的新胰岛素类似物 | |
| HRP20090597T1 (hr) | Muteini čimbenika rasta fibroblasta 21 | |
| MX2009009022A (es) | Vacunas de peptídicas para cánceres que expresan antígenos asociados con tumores. | |
| Michael Conlon et al. | Design of potent, non‐toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin‐8 and peptide XT‐7 | |
| NZ597306A (en) | Mesenchymal stem cell differentiation | |
| EP1969003B8 (fr) | Utilisations d'un FACTEUR NEUROTROPHIQUE | |
| KR20200101953A (ko) | 보툴리눔 독소 세포 결합 도메인 폴리펩티드 및 섬유증 연관 장애의 치료를 위한 사용 방법 | |
| RU2013151875A (ru) | Модифицированная кислая альфа глюкозидаза с ускоренным процессингом | |
| Conlon et al. | Antimicrobial properties of brevinin‐2‐related peptide and its analogs: efficacy against multidrug‐resistant Acinetobacter baumannii | |
| KR101444261B1 (ko) | 왕지네로부터 분리한 신규 스콜로펜드라신ⅰ펩타이드 및 그의 조성물 | |
| JP2008518622A5 (fr) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: THE UNITED STATES OF AMERICA, US Effective date: 20210921 Owner name: NOVO NORDISK A/S, DK Effective date: 20210921 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2025 BY ANAQUA SERVICES Effective date: 20231220 |